Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
about
Novel strategies to target the ubiquitin proteasome system in multiple myelomaMolecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.p53 abnormalities and potential therapeutic targeting in multiple myeloma.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Targeting p53 by small molecules in hematological malignancies.RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.Avoiding drug resistance through extended drug target interfaces: a case for stapled peptidesThe clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.Resistance acquisition to MDM2 inhibitors.Pharmacological activation of wild-type p53 in the therapy of leukemia.The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiationA lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
P2860
Q26773246-E42969EC-F8B0-4757-A54C-179D2A4FDED5Q28074490-DE8D406A-E8F0-478E-86B1-E0196ECA6F66Q28542684-6ED4A819-F889-4999-80FB-9918BD29B38AQ33709483-1102A3D0-9DF2-4EA4-9629-482CC02BB269Q33852683-9E4954B1-10A0-4111-A579-BB05E3E39F72Q33869257-EA357BF5-F26E-4188-A83F-4BA06F035C21Q34636996-7AE379D0-7EFA-47B9-96E8-09C63C732F51Q35187880-916BEC34-8F47-484A-899B-F7D19EBF2548Q37362651-5B190B21-D020-4EF8-8F63-9DD54C0ABDA4Q38192005-FAA89309-02F8-4B14-A6B4-662DD0033780Q38238600-3A683912-09DE-4B32-BB11-4D3D51AF868CQ38872029-C51113E3-1206-4F62-859E-8DEC01A70E4BQ39029195-9CFC4E06-10A6-468B-BF96-E2928B7F6B8BQ39439144-E3BD66A6-1BA9-4D8F-A534-66F2E628A844Q40854245-09E176CD-17A5-4295-AA90-9E0569748C8AQ41362934-F15224D3-CE5D-4C36-B5DD-A679DA1BBA03Q46356056-CE557ED0-055A-4949-9236-C87B1BDC27EBQ50020971-AFD70915-90E0-4CC2-9027-FDEFAF7B4EF8
P2860
Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@ast
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@en
type
label
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@ast
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@en
prefLabel
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@ast
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@en
P2093
P2860
P1476
Drug resistance to inhibitors ...... the p53 targeting agent RITA.
@en
P2093
Chad C Bjorklund
Deborah J Kuhn
Richard J Jones
Veerabhadran Baladandayuthapani
P2860
P304
P356
10.1158/1535-7163.MCT-12-0135
P577
2012-08-28T00:00:00Z